Mark L Sparacino is a notable inventor based in Morgan Hill, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel therapeutic compounds. With a total of 3 patents, his work has had a substantial impact on antiviral therapies.

Latest Patents

Sparacino's latest patents include innovative methods for creating prodrugs of phosphonate nucleotide analogues. This novel method has led to the identification of mixed ester-amidates of PMPA, which are promising for retroviral or hepadnaviral therapy. The patent details compositions of these compounds in pharmaceutically acceptable excipients and their therapeutic applications. Another significant patent involves the cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds. These compounds exhibit HIV protease inhibitory properties and are useful therapeutically for treating AIDS and other antiviral infections.

Career Highlights

Mark L Sparacino is currently associated with Gilead Sciences, Inc., a leading biopharmaceutical company. His work at Gilead has focused on developing innovative therapies that address critical health challenges. His contributions have been instrumental in advancing the understanding and treatment of viral infections.

Collaborations

Throughout his career, Sparacino has collaborated with esteemed colleagues, including Gong-Xin He and William A Lee. These collaborations have fostered a productive environment for innovation and research in pharmaceutical sciences.

Conclusion

Mark L Sparacino's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and contributions continue to pave the way for advancements in antiviral therapies.

Profile summary based on public USPTO records.